Of interest, recently, HER2 “low” breast cancers, those showing 1 + score by IHC or 2 + with negative ISH, have demonstrated some remarkable response rates and progression-free survival after Her2 antibody-drug conjugates (ADC) treatments [15]. The gene discussed is ERBB2; the disease is breast carcinoma.